Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005853 · ClinicalTrials.gov registry record · Phase 2
Biological Therapy in Treating Patients With Myelodysplastic Syndrome
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00005853: Completed Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
NCT00005853 is a Phase 2 study that has completed, run by Fred Hutchinson Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005853, a Phase 2 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of biological therapy in treating patients who have myelodysplastic syndrome.
Interventions
- BIOLOGICAL anti-thymocyte globulin
- BIOLOGICAL etanercept
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-12 |
| Est. Completion | 2005-08 |
| Phase | Phase 2 |
What the finished NCT00005853 record still lists
NCT00005853 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which anti-thymocyte globulin is the first listed.
NCT00005853 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005853 about?
NCT00005853 is a clinical study titled "Biological Therapy in Treating Patients With Myelodysplastic Syndrome". RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of biological therapy in treating patients who have ...
What is the current status of trial NCT00005853?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-12. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00005853?
The interventions under investigation include: anti-thymocyte globulin (BIOLOGICAL), etanercept (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005853?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia